Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Extracts

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Extracts. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-003270-28 Sponsor Protocol Number: VB-02-DFLOP Start Date*: 2014-01-27
    Sponsor Name:Instituto de Inmunología y Alergia INMUNAL S.A..U.
    Full Title: Biological standardization of allergenic extracts of Dermatophagoides farinae and Lolium perenne. Open label. Single Center. Phase II Study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002644-24 Sponsor Protocol Number: DIA-STA--11-01-19 Start Date*: 2020-03-11
    Sponsor Name:Diater, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas S.A.
    Full Title: Biological standarization of allergic extracts of will grasses: Phleum pratense, Lolium perenne, Poa pratensis y Dactylis glomerata and its mixture to determinate their biological activity, the In ...
    Medical condition: Biological standarization for allergenic extracts in patients with hipersensibility to extract
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003892-36 Sponsor Protocol Number: VB-03-PASKCHAV Start Date*: 2015-07-22
    Sponsor Name:INMUNAL SAU
    Full Title: Biological standardization of allergenic extracts of Platanus acerifolia, Salsola kali, Chenopodium album y Artemisia vulgaris . Open label. Multicenter. Phase II Study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001210-26 Sponsor Protocol Number: PRO-VB-GRA-03 Start Date*: 2015-08-12
    Sponsor Name:PROBELTE PHARMA S.A.
    Full Title: Biological standardization of allergen extracts of pollen of Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense and Poa pratensis in patients sensitized to them.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005362-35 Sponsor Protocol Number: VB-01-DPHLOLEG Start Date*: 2013-04-09
    Sponsor Name:Instituto de Inmunología y Alergia INMUNAL SAU
    Full Title: Biological standardization of pollen of Phleum pratense, Olea europaea, mite extract Dermatophagoides pteronyssinus and animal allergen Felis domesticus. Open label, single center, phase II study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001651-39 Sponsor Protocol Number: BIGRADE-IHR-12 Start Date*: 2012-11-14
    Sponsor Name:LOFARMA
    Full Title: In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units
    Medical condition: Respiratory allergopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    14.1 10021428 - Immune system disorders 10001742 Allergy to animal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005529-25 Sponsor Protocol Number: API-EAG-2021-01 Start Date*: 2022-10-14
    Sponsor Name:ASAC Pharmaceutical Inmunology, S.A.
    Full Title: In vivo Biological Standardization of Gramineae Allergenic Extracts
    Medical condition: Biological standarization for allergenic extracts in patients with hipersensibility to extract
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005471-88 Sponsor Protocol Number: MG56-SIT-012 Start Date*: 2015-11-27
    Sponsor Name:INMUNOTEK, S.L.
    Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against grass pollen allergy
    Medical condition: Grass pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011999-30 Sponsor Protocol Number: VO64.08 Start Date*: 2009-09-16
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets on...
    Medical condition: House Dust Mite Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) FR (Completed) DK (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004223-46 Sponsor Protocol Number: SL75.14 Start Date*: 2015-09-16
    Sponsor Name:Stallergenes
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with ...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001725 Allergic rhinitis due to other allergen LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) SK (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003715-22 Sponsor Protocol Number: DMV01-SIT-015 Start Date*: 2020-11-04
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomized, placebo-controlled, multi-center trial comparing the efficacy and safety of subcutaneous immunotherapy with a mixture of grasses and mites at adequate doses versus monother...
    Medical condition: Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001571-31 Sponsor Protocol Number: 6078-PG-PSC-204 Start Date*: 2014-10-23
    Sponsor Name:Laboratorios LETI, S.L. Unipersonal
    Full Title: A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali...
    Medical condition: Patients with allergic rhinitis or rhinoconjunctivitis, with or without asthma, controlled by triple sensitization to grass pollen, Olea europaea and Salsola kali, susceptible to treatment with imm...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002811-25 Sponsor Protocol Number: DMV03-SIT-027 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjun...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002865-37 Sponsor Protocol Number: DMV02-SIT-026 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With or Without...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003000-35 Sponsor Protocol Number: Final Version 1.0 Hyposensitisation Start Date*: 2007-07-09
    Sponsor Name:Department of Occupational and Environmental Dermatology, Malmö University Hospital
    Full Title: A randomized controlled single blind multicenter study to investigate the induction of aluminium contact allergy in children/adults receiving hyposensitisation therapy due to allergic disease. Chi...
    Medical condition: The development of contact allergy to aluminium during hyposensitization therapy.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000672-42 Sponsor Protocol Number: BIA-STD-003 Start Date*: 2012-10-11
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them.
    Medical condition: Treatment and diagnosis of allergy to Artemisa vulgaris, Platanus acerifolia and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    14.1 10021428 - Immune system disorders 10066092 Acaridae allergy LLT
    14.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015679-28 Sponsor Protocol Number: RHM CHI0499 Start Date*: 2010-09-29
    Sponsor Name:Southampton University Hospitals Trust
    Full Title: PRIMARY PREVENTION OF ATOPY AND ASTHMA WITH ALLERGEN SUBLINGUAL IMMUNOTHERAPY
    Medical condition: Development of atopy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019857 Hereditary allergy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005207-42 Sponsor Protocol Number: 2005079 Start Date*: 2005-12-29
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A study to assess the efficacy of a combination of natural plant extracts in natural colds.
    Medical condition: Common Cold (nasopharyngitis), Upper Respiratory Tract Infection
    Disease: Version SOC Term Classification Code Term Level
    8.0 10028810 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:37:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA